相关实验视频
Updated: Jul 24, 2025

Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
PAX5-miR-142反循环通过调节 DNMT1 和 ZEB1 来促进乳腺癌的扩散
Zhao-Hui Chen1,2,3,4, Yi-Bo Chen1,2,3,4,5, Hao-Ran Yue1,2,3,4
1The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huan-Hu-Xi Road, He-Xi District, Tianjin, 300060, China.
通过调节miR-142.5,PAX5在乳腺癌中起到瘤抑制作用. 这一途径涉及DNMT1和ZEB1的甲基化,形成一个反循环,影响癌症的进展,并提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 乳腺癌是一个全球性的健康问题,微RNAs (miRNAs) 和表观遗传修饰在它的发展中起着关键作用.
- 以前的研究确定了miR-142-3p作为瘤抑制剂,准CDC25C,但其精确的机制仍然不清楚.
研究的目的:
- 为了阐明乳腺癌中miR-142的上游调节机制.
- 研究PAX5在乳腺癌进展中的作用及其与miR-142的相互作用.
主要方法:
- 使用生物信息学,PAX5被确定为miR-142-5p / 3p的上游调节器,并通过体外和体内测试进行验证.
- 分析了PAX5表达,促进物甲基化 (使用BSP测序),以及与DNMT1和ZEB1的相互作用 (使用光酶试验,ChIP和co-IP).
主要成果:
- 帕克斯5作为瘤抑制剂,积极调节miR-142-5p/3p的表达.
- DNMT1和ZEB1诱导PAX5促进体的甲基化,影响其表达.
- miR-142-5p/3p直接准并调节DNMT1和ZEB1.1的表达.
结论:
- 建立了一个涉及PAX5,miR-142,DNMT1和ZEB1的负反循环,调节乳腺癌的进展.
- 这个监管网络为乳腺癌治疗提出了新的治疗目标和策略.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
相关概念视频
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Epigenetic Regulation
X-chromosome...
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway